HOME >> MEDICINE >> NEWS
Proteome Systems signs agreement with Prince Henry's Institute for Ovarian Cancer Diagnostic Test

Sydney, Australia: Proteome Systems (ASX:PXL) today announced a collaboration with Prince Henry's Institute Medical Research (PHIMR) to combine their IP and expertise in ovarian cancer for the discovery and development of novel diagnostic markers.
  • If ovarian cancer is detected early there is a very good prognosis for full recovery. Currently, there is no test for early detection of ovarian cancer.
  • PXL has patented several protein and carbohydrate candidate markers for the development of an ovarian cancer diagnostic test.
  • Melbourne-based PHIMR has previously developed a test to detect ovarian cancer in post-menopausal woman, a significant sector of the target population.

Of all the gynaecologic cancers, ovarian malignancies represent the greatest clinical challenge. Around 1 in 56 women will develop ovarian cancer during their lifetime. Due to the absence of clear symptoms, ovarian cancer is usually detected when it has already spread beyond the ovary. At this relatively late stage the 5 year survival rate has decreased to ~30% while if the cancer is detected when confined to the ovary, the corresponding 5-year survival rate is >85%. This has led to the need to develop markers that can detect ovarian cancer at this early stage.

Proteome Systems has discovered and patented novel markers for epithelial ovarian cancer using its proprietary proteomic and glycoproteomic technology platforms. The company is actively seeking partnerships with academic and clinical groups with expertise in ovarian cancer to further expand its portfolio of ovarian cancer markers and clinically evaluate these for the development of a diagnostic test.

Associate Professor David Robertson leads the team at PHIMR that has previously developed a test to diagnose ovarian cancer (Robertson et al., 2002; Robertson and Oehler, 2005). The test is useful for initial diagnosis and monitoring recurrence of the disease in post-menopausal women, but i
'"/>

Contact: Jenny Harry
61-2-8877-8947
Research Australia
12-Oct-2005


Page: 1 2

Related medicine news :

1. Proteome Systems Ltd and US-based Egenix Inc to develop semen-based test for prostate cancer
2. Proteome Systems raises $10m through a private placement to institutional and professional investors
3. Ossur v. Bledsoe Brace Systems
4. Pot bellies linked to early signs of cardiovascular disease
5. Heading to Siberia: UH signs agreement with Russian Academy of Sciences
6. Most young women dont recognize heart attack warning signs
7. Mice with a migraine show signs of brain damage
8. New cigarette designs dont offer lower predicted cancer risks
9. USP signs Memorandum of Understanding with the Pharmaceutical Export Promotion Council
10. Noise-immune stethoscope helps medics hear vital signs in loud environments
11. Before dementias first signs appear, weight-loss rate doubles in elderly

Post Your Comments:
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 State Forestry Institute of Mecklenburg-Vorpommern ... with support from GEOSYSTEMS, a dedicated Hexagon Geospatial and ... leverage Hexagon Geospatial’s ERDAS APOLLO for cataloging, ... as point clouds and documents. This effort will enable ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
(Date:1/22/2015)... THOUSAND OAKS, Calif. , Jan. 22, 2015  Amgen (NASDAQ: ... quarter and full year 2014 financial results on Tuesday, Jan. 27, ... will be followed by a conference call with the investment community ... be Robert A. Bradway , chairman and chief executive officer, ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
Cached News: